Currently Enrolling
Interventional

The AFFINITY Study

Atrasentan for Patients with Proteinuric Glomerular Diseases

The AFFINITY study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy, focal segmental glomerulosclerosis, Alport Syndrome, and diabetic kidney disease.

Currently Enrolling
Interventional

The AFFINITY Study

Atrasentan for Patients with Proteinuric Glomerular Diseases

The AFFINITY study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy, focal segmental glomerulosclerosis, Alport Syndrome, and diabetic kidney disease.

Eligibility Criteria
Patient Population

Iga Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), Alport Syndrome, and Diabetic Kidney Disease (DKD)

Age

18 — 26+

History of transplant allowed?

No

History of dialysis allowed?

No

eGFR

30 — > 60

UPCR

1.0 or Less — 3.0 or Above

Permitted medication history

Ace Inhibitors/ARB, Rituximab (AKA Rituxan), Other, Prograf (AKA Tacrolimus), Acthar, Cellcept (AKA Mycophenolate), Cytoxan (Cyclophosphamide), Abatacept, Prednisone (Steroids)

Patient should be

Neither of These

About the Drug
What is involved for the patient

Patients will participate for about 1 year and will receive atrasentan.

Sponsor

Chinook Therapeutics

Estimated End Date

December 2024

About the Trial
Study Drug

Atrasentan

Study Goal

The goal of the study is to evaluate the effect of atrasentan on proteinuria in patients with IgAN, FSGS, Alport Syndrome, or in combination with SGLT2 inhibitors in DKD.

About the drug or intervention

Atrasentan is a tablet taken orally once a day.

San Dimas, CA
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions